281 related articles for article (PubMed ID: 22681512)
41. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
Fernández Ó
Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
Wade D
Expert Rev Neurother; 2012 Apr; 12(4 Suppl):9-14. PubMed ID: 22509986
[TBL] [Abstract][Full Text] [Related]
43. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
44. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Patti F; Messina S; Solaro C; Amato MP; Bergamaschi R; Bonavita S; Bruno Bossio R; Brescia Morra V; Costantino GF; Cavalla P; Centonze D; Comi G; Cottone S; Danni M; Francia A; Gajofatto A; Gasperini C; Ghezzi A; Iudice A; Lus G; Maniscalco GT; Marrosu MG; Matta M; Mirabella M; Montanari E; Pozzilli C; Rovaris M; Sessa E; Spitaleri D; Trojano M; Valentino P; Zappia M;
J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):944-51. PubMed ID: 27160523
[TBL] [Abstract][Full Text] [Related]
46. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
Carotenuto A; Iodice R; Petracca M; Inglese M; Cerillo I; Cocozza S; Saiote C; Brunetti A; Tedeschi E; Manganelli F; Orefice G
Acta Neurol Scand; 2017 Apr; 135(4):442-448. PubMed ID: 27500463
[TBL] [Abstract][Full Text] [Related]
47. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
48. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
Wade DT; Collin C; Stott C; Duncombe P
Mult Scler; 2010 Jun; 16(6):707-14. PubMed ID: 20558502
[TBL] [Abstract][Full Text] [Related]
49. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Haupts MR; Essner U; Mäurer M
Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
[TBL] [Abstract][Full Text] [Related]
50. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
51. Advances in the management of MS symptoms: recently proposed clinical management algorithms.
Vermersch P
Neurodegener Dis Manag; 2015; 5(6 Suppl):23-6. PubMed ID: 26611268
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
[TBL] [Abstract][Full Text] [Related]
53. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Serpell MG; Notcutt W; Collin C
J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
[TBL] [Abstract][Full Text] [Related]
54. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
Gold R; Oreja-Guevara C
Expert Rev Neurother; 2013 Dec; 13(12 Suppl):55-9. PubMed ID: 24289845
[TBL] [Abstract][Full Text] [Related]
55. Advances in the management of MS spasticity: recent observational studies.
Fernández O
Eur Neurol; 2014; 72 Suppl 1():12-4. PubMed ID: 25278118
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
Trojano M; Vila C
Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity.
Bensmail D; Ward AB; Wissel J; Motta F; Saltuari L; Lissens J; Cros S; Beresniak A
Neurorehabil Neural Repair; 2009; 23(6):546-52. PubMed ID: 19228818
[TBL] [Abstract][Full Text] [Related]
59. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
60. Intrathecal baclofen in multiple sclerosis: too little, too late?
Erwin A; Gudesblatt M; Bethoux F; Bennett SE; Koelbel S; Plunkett R; Sadiq S; Stevenson VL; Thomas AM; Tornatore C; Zaffaroni M; Hughes M
Mult Scler; 2011 May; 17(5):623-9. PubMed ID: 21282321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
